|Dr. Carlos de Sousa||Chief Exec. Officer||N/A||N/A||1958|
|Mr. Hans Vassgård Eid||Chief Financial Officer||N/A||N/A||N/A|
|Ms. Ingunn Hagen Westgaard Ph.D.||Head of Research||N/A||N/A||N/A|
|Mr. Audun Tornes||Chief Technology Officer||N/A||N/A||N/A|
|Mr. Jens Egil Torbjorn Bjorheim M.D., Ph.D.||Chief Medical Officer||N/A||N/A||N/A|
|Mr. Oivind Foss Ph.D.||Head of Clinical Operations||N/A||N/A||N/A|
|Ms. Gudrun Troite Ph.D.||Head of Project Coordination||N/A||N/A||N/A|
|Mr. Antonius Berkien||Chief Bus. Officer||N/A||N/A||1968|
|Prof. Gustav Gaudernack Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Ms. Anne H. Worsoe||Head of Investor Relations & Communication||N/A||N/A||N/A|
Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.
Ultimovacs ASA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.